Advertisement
ISRG or MDT or SYK
Which Stock Would AI Choose? Intuitive Surgical (ISRG) vs. Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Three different profiles: ISRG is a high-growth robotic-surgery pure play, MDT is a diversified value-and-dividend medtech giant, and SYK is a growth-oriented orthopedic and capital-equipment leader.
- Momentum diverges sharply: ISRG and SYK are trading well below their 52-week highs, while MDT has been comparatively steady but has lagged the broader market over the past year.
- Valuation gap is wide: ISRG carries a premium multiple near 48 times earnings, SYK sits near 20 times forward earnings, and MDT trades at roughly 15–16 times forward earnings with a dividend yield above 3%.
- Distinct catalysts: ISRG's da Vinci 5 upgrade cycle, MDT's MiniMed spin-off and new CPT codes, and SYK's Mako robotics momentum and CEO transition are shaping each stock's outlook.
- Risk profiles differ: ISRG faces slowing procedure growth and competition, MDT faces execution and restructuring uncertainty, and SYK is still working through cybersecurity recovery and supply disruptions.
Introduction
Investors screening medical technology names often encounter the same trio: ISRG, MDT, and SYK. Though all three operate in medical devices, they serve different strategies and risk appetites. This stock comparison examines their relative performance, market positioning, and growth drivers to help traders and long-term investors understand where each name stands in the current market environment. Growth-oriented investors weighing robotic-surgery exposure, income-focused buyers seeking stability and dividends, and momentum traders assessing recovery plays can all find relevant context here.
ISRG Overview and Recent Performance
Intuitive Surgical is the pioneer and dominant player in robot-assisted minimally invasive surgery, led by its da Vinci platform and the newer Ion lung-biopsy system. The business is built on a recurring-revenue model, with instruments, accessories, and servicing now accounting for roughly 86% of total sales. In recent market activity, however, the stock has been a notable laggard, down meaningfully from its January high and trading near its 52-week low despite posting strong underlying results in recent quarters.
Sentiment has been pressured by several factors in recent weeks and months: moderating da Vinci procedure growth, softer bariatric (weight-loss surgery) volumes tied to rising use of GLP-1 (glucagon-like peptide-1) drugs, increased competition in China, and broader investor concern about AI and robotics rivals. These worries have overshadowed encouraging fundamentals, including the da Vinci 5 upgrade cycle, growing placements, and rising revenue per procedure. With the stock trading at a premium valuation near 48 times earnings, the market is demanding continued execution even as procedure-growth expectations reset lower.
MDT Overview and Recent Performance
Medtronic is one of the world's largest and most diversified medical device makers, spanning cardiovascular, neuroscience, medical-surgical, and diabetes care. Unlike its two peers here, it offers investors a substantial dividend—raised for 49 consecutive years—alongside a lower, value-oriented valuation. In recent quarters, the company has accelerated revenue growth, with its latest fiscal quarter showing double-digit gains, partly aided by an extra selling week, and management has signaled its strongest underlying performance in nearly eight years.
The stock's recent behavior reflects a restructuring story. Medtronic has spun off its diabetes unit as MiniMed to sharpen focus on higher-margin businesses, while advancing its Hugo robotic-assisted surgery system, its Affera pulsed field ablation (PFA) platform for atrial fibrillation, and its Symplicity Spyral renal denervation system. Regulatory wins, including new permanent CPT (Current Procedural Terminology) codes for two of its therapies, have supported the long-term case, though those reimbursements take effect later. Despite this progress, shares have traded in a range and lagged the broader market over the past year, as investors weigh execution risk against an inexpensive valuation and an attractive yield.
SYK Overview and Recent Performance
Stryker is a leading manufacturer of orthopedic implants, surgical equipment, and neurotechnology, best known for its Mako robotic-arm-assisted surgery system. The company has posted strong recent results—second-quarter adjusted earnings rose roughly 18% year over year on about 9% organic sales growth—as it recovered from a March cybersecurity incident that disrupted manufacturing and ordering and weighed on first-quarter results. Record Mako installations and rising utilization across its installed base have reinforced the growth narrative.
Yet the stock has fallen substantially from its 52-week high, partly on the cyber incident, lingering supply disruptions in its vascular business, and a planned CEO transition in which Spencer Stiles will succeed Kevin Lobo at the start of 2027. Broader pressure on medical-device valuations has also contributed. Still, the shares now trade near the low end of their recent valuation range, and analysts remain constructive, citing a deep product pipeline and margin-expansion potential. The near-term question is whether operational execution can convert those catalysts into sustained momentum.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each built around its own trading style, strategy, timeframe, performance record, statistics, and watchlist of symbols. Because no single approach fits every market condition, only the bots best suited to the current environment are highlighted in the curated Trending AI Robots section. These featured robots span a range of methodologies—from short-term swing trading to longer-horizon trend following—and are evaluated on consistency and adaptability rather than past returns alone. For investors comparing names like ISRG, MDT, and SYK, exploring the Trending AI Robots page can offer an additional, data-driven perspective on which setups currently align with algorithmic signals.
Head-to-Head Comparison
The clearest contrast among these three stocks is business model and growth profile. ISRG is a focused, high-margin growth engine with a razor-and-blades recurring-revenue structure, commanding a premium multiple to match. MDT is a diversified, cash-generating incumbent trading at a discount to the broader market, with a dividend that appeals to income investors but slower structural growth. SYK sits in between, blending steady orthopedic demand with meaningful exposure to capital equipment and robotics.
Recent momentum also diverges. ISRG and SYK have both experienced sharp drawdowns from prior highs, creating potential rebound setups but also reflecting genuine headwinds. MDT has been less volatile but has underperformed over longer windows. On risk, ISRG's valuation is its biggest vulnerability, while MDT's restructuring and SYK's post-cyber recovery and leadership handover represent company-specific execution risks. All three share exposure to hospital capital budgets and elective procedure volumes, making them broadly sensitive to the same macro-healthcare forces.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalyst visibility, and relative positioning, Tickeron's AI would likely favor MDT in the current environment. Its lower valuation, supported dividend, improving revenue momentum, and multiple regulatory catalysts offer a comparatively stable risk-reward profile with less downside volatility than its two peers. SYK presents the strongest earnings momentum and analyst conviction, but its execution and leadership-transition variables introduce near-term uncertainty. ISRG retains the most compelling long-term growth story, yet its premium valuation and moderating procedure growth make its trend harder to defend in the short term. These conclusions are probabilistic, based on current signals, and should be viewed as one input among many rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for ISRG shows an upward move is likely
ISRG's Aroon Indicator triggered a bullish signal on October 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 264 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 264 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 54 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The 10-day moving average for ISRG crossed bullishly above the 50-day moving average on September 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.795) is normal, around the industry mean (4.989). P/E Ratio (51.164) is within average values for comparable stocks, (37.210). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
MDT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for MDT moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 48 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 27 of 43 cases over the following month. The odds of a continued upward trend are 63%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 170 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 12 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MDT broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 24 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.430) is normal, around the industry mean (2.906). P/E Ratio (23.328) is within average values for comparable stocks, (2.003). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.052). Dividend Yield (0.030) settles around the average of (0.009) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
SYK in +3.21% Uptrend, growing for three consecutive days on October 23, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 49 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 21 of 44 cases over the following month. The odds of a continued upward trend are 48%.
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.911) is normal, around the industry mean (2.906). P/E Ratio (31.567) is within average values for comparable stocks, (2.003). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.011) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ISRG | MDT | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 40 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 58 Fair valued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 72 | 100 | 75 | |
SMR RATING 1..100 | 51 | 68 | 52 | |
PRICE GROWTH RATING 1..100 | 42 | 24 | 52 | |
P/E GROWTH RATING 1..100 | 76 | 55 | 83 | |
SEASONALITY SCORE 1..100 | 43 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (58) in the Medical Specialties industry is in the same range as SYK (77) and is in the same range as ISRG (81). This means that MDT's stock grew similarly to SYK’s and similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as SYK (75) and is in the same range as MDT (100). This means that ISRG's stock grew similarly to SYK’s and similarly to MDT’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as SYK (52) and is in the same range as MDT (68). This means that ISRG's stock grew similarly to SYK’s and similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (24) in the Medical Specialties industry is in the same range as ISRG (42) and is in the same range as SYK (52). This means that MDT's stock grew similarly to ISRG’s and similarly to SYK’s over the last 12 months.
MDT's P/E Growth Rating (55) in the Medical Specialties industry is in the same range as ISRG (76) and is in the same range as SYK (83). This means that MDT's stock grew similarly to ISRG’s and similarly to SYK’s over the last 12 months.
| ISRG | MDT | SYK | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 32% | 2 days ago 46% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 51% | 2 days ago 48% | 2 days ago 50% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 56% | 2 days ago 54% |
| MACD ODDS (%) | N/A | 2 days ago 63% | 2 days ago 48% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 56% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 66% | 2 days ago 50% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 66% | 10 days ago 54% | 2 days ago 56% |
| Declines ODDS (%) | 11 days ago 61% | 6 days ago 56% | 11 days ago 52% |
| BollingerBands ODDS (%) | 2 days ago 49% | 2 days ago 53% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 46% | 2 days ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISRG’s FA Score shows that 0 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s), and SYK’s FA Score reflects 0 green FA rating(s).
- ISRG’s FA Score: 0 green, 5 red.
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISRG’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s), and SYK’s TA Score reflects 5 bullish TA indicator(s).
- ISRG’s TA Score: 4 bullish, 4 bearish.
- MDT’s TA Score: 6 bullish, 5 bearish.
- SYK’s TA Score: 5 bullish, 4 bearish.
Price Growth
ISRG (@Pharmaceuticals: Other) experienced а +6.00% price change this week, while MDT (@Medical/Nursing Services) price change was +0.70% , and SYK (@Medical/Nursing Services) price fluctuated +4.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.78%. For the same industry, the average monthly price growth was -3.41%, and the average quarterly price growth was +7.38%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.51%. For the same industry, the average monthly price growth was -9.72%, and the average quarterly price growth was -10.64%.
Reported Earning Dates
ISRG is expected to report earnings on Jan 26, 2027.
MDT is expected to report earnings on Nov 17, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+2.78% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.51% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.